Who
Marianne De Backer
President and CEO
Company insider
Files Form 4 as: President and CEO, Vir Biotechnology; Director, Kronos Bio; Director, Arrowhead Pharmaceuticals.
In numbers
- Trades disclosed
- 53
- Buys
- 12
- Sells
- 8
- Bought
- $233K
- Sold
- $4.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 1 Jan 2020
- Last trade
- 29 Apr 2026
- Last filed
- 30 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Apr 2026filed 30 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —233,532 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —233,532 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —233,532 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —233,532 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $664K72,559 at $9.16 | filing |
| 6 Apr 2026filed 7 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $665K72,559 at $9.16 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $141K14,762 at $9.53 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $141K14,762 at $9.53 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $142K19,039 at $7.45 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $142K19,039 at $7.45 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —570,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —570,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 3 Apr 2025filed 4 Apr 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $474K79,712 at $5.95 | filing |
| 24 Feb 2025filed 25 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $152K16,122 at $9.45 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —480,000 at $0.00 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 12 Jun 2024filed 12 Jun 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —53,118 at $0.00 | filing |
| 12 Jun 2024filed 12 Jun 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —53,118 at $0.00 | filing |
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Marianne De Backer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.